CA1335711C - Methode pour accroitre l'effet antagoniste de composes peptidiques sur les affections hormonodependantes - Google Patents

Methode pour accroitre l'effet antagoniste de composes peptidiques sur les affections hormonodependantes

Info

Publication number: CA1335711C
Authority: CA; Canada
Prior art keywords: formulation; analog; trp; leu; pyro
Prior art date: 1987-05-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 566908

Other languages

English (en)

Inventor

Thomas Robert Tice

Andrew Victor Schally

Piero Orsolini

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Debio Recherche Pharmaceutique SA

Original Assignee

Debiopharm SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-05-19

Filing date

1988-05-16

Publication date

1995-05-30

1987-05-19 Priority claimed from US07/052,319 external-priority patent/US4835139A/en

1988-05-16 Application filed by Debiopharm SA filed Critical Debiopharm SA

1995-05-30 Application granted granted Critical

1995-05-30 Publication of CA1335711C publication Critical patent/CA1335711C/fr

2012-05-30 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 33
230000003042 antagnostic effect Effects 0.000 title claims abstract description 15
229940088597 hormone Drugs 0.000 title claims abstract description 13
239000005556 hormone Substances 0.000 title claims abstract description 13
201000010099 disease Diseases 0.000 title claims abstract description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
230000001419 dependent effect Effects 0.000 title claims abstract description 10
238000000034 method Methods 0.000 title description 13
230000008569 process Effects 0.000 title description 10
229920001577 copolymer Polymers 0.000 claims abstract description 25
WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims abstract description 17
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims abstract description 16
238000000576 coating method Methods 0.000 claims abstract description 10
239000011248 coating agent Substances 0.000 claims abstract description 9
238000002347 injection Methods 0.000 claims abstract description 8
239000007924 injection Substances 0.000 claims abstract description 8
125000000217 alkyl group Chemical group 0.000 claims abstract description 5
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims abstract description 5
239000011159 matrix material Substances 0.000 claims abstract description 5
230000004936 stimulating effect Effects 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims description 43
238000009472 formulation Methods 0.000 claims description 39
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 16
JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 11
230000001629 suppression Effects 0.000 claims description 9
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 claims description 7
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 7
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 7
230000000144 pharmacologic effect Effects 0.000 claims description 7
230000000803 paradoxical effect Effects 0.000 claims description 5
239000002245 particle Substances 0.000 claims description 5
238000010255 intramuscular injection Methods 0.000 claims description 4
239000007927 intramuscular injection Substances 0.000 claims description 4
238000013268 sustained release Methods 0.000 claims description 4
239000012730 sustained-release form Substances 0.000 claims description 4
229920000642 polymer Polymers 0.000 claims description 3
239000012798 spherical particle Substances 0.000 claims description 2
230000005855 radiation Effects 0.000 claims 4
BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims 2
238000005538 encapsulation Methods 0.000 abstract description 7
239000003488 releasing hormone Substances 0.000 abstract description 5
230000015572 biosynthetic process Effects 0.000 abstract 1
229940126062 Compound A Drugs 0.000 description 26
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 26
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 26
229960003604 testosterone Drugs 0.000 description 13
238000002360 preparation method Methods 0.000 description 11
239000011859 microparticle Substances 0.000 description 10
230000000694 effects Effects 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
230000002354 daily effect Effects 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000002831 pharmacologic agent Substances 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 4
239000003094 microcapsule Substances 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000037396 body weight Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 2
238000013019 agitation Methods 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
-1 matric compound Chemical class 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KTVPQHFLYINKPT-LVHVEONVSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-o Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 KTVPQHFLYINKPT-LVHVEONVSA-N 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000005354 coacervation Methods 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005070 sampling Methods 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CA 566908 1987-05-19 1988-05-16 Methode pour accroitre l'effet antagoniste de composes peptidiques sur les affections hormonodependantes Expired - Fee Related CA1335711C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US052,319		1987-05-19
US07/052,319 US4835139A (en)	1983-09-23	1987-05-19	Process for increasing the antagonistic effect of peptidic compounds on hormone-dependent diseases

Publications (1)

Publication Number	Publication Date
CA1335711C true CA1335711C (fr)	1995-05-30

Family

ID=21976827

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 566908 Expired - Fee Related CA1335711C (fr)	1987-05-19	1988-05-16	Methode pour accroitre l'effet antagoniste de composes peptidiques sur les affections hormonodependantes

Country Status (1)

Country	Link
CA (1)	CA1335711C (fr)

1988
- 1988-05-16 CA CA 566908 patent/CA1335711C/fr not_active Expired - Fee Related

Legal Events

Date	Code	Title	Description
2006-05-30	MKLA	Lapsed

Publication	Publication Date	Title
US4835139A (en)	1989-05-30	Process for increasing the antagonistic effect of peptidic compounds on hormone-dependent diseases
US4675189A (en)	1987-06-23	Microencapsulation of water soluble active polypeptides
EP0301856B1 (fr)	1995-05-24	Dispositif libérant des produits pharmaceutiques
EP0302582B1 (fr)	1994-07-27	Système pour la libération de drogues et son mode de préparation
NL193818C (nl)	2000-12-04	Farmaceutisch vast preparaat voor vertraagde en beheerste afgifte van een therapeutisch werkzame polypeptide verbinding.
RU2098121C1 (ru)	1997-12-10	Микрокапсула для длительного высвобождения физиологически активного пептида
EP0052510B1 (fr)	1986-08-27	Microencapsulation de polypeptides hydrosolubles
CA2316159C (fr)	2008-04-29	Microcapsules a liberation lente
JP4361144B2 (ja)	2009-11-11	徐放性製剤
JPS60228411A (ja)	1985-11-13	インプラント可能な組成物およびその製造方法
PT98025A (pt)	1992-06-30	Processo para a preparacao de implantes veterinarios revestidos com alcool polivinilico,contendo nomeadamente uma hormona de crescimento
JP5721635B2 (ja)	2015-05-20	一定して高い曝露レベルを有するオクトレオチドのデポー製剤
CZ306388B6 (cs)	2017-01-04	Kompozice s trvalým uvolňováním a způsob její výroby
KR19990037094A (ko)	1999-05-25	약물 방출 속도가 제어된 의약 조성물
RU2004102507A (ru)	2005-03-10	Композиция с регулируемым высвобождением и способ ее получения
CA2178592C (fr)	2009-07-28	Suspensions pour injection a action prolongee et procede de preparation
CA1335711C (fr)	1995-05-30	Methode pour accroitre l'effet antagoniste de composes peptidiques sur les affections hormonodependantes
JP5601749B2 (ja)	2014-10-08	徐放性組成物、その製造法および用途
WO1996010395A1 (fr)	1996-04-11	Preparations pharmaceutiques a liberation lente
KR0140209B1 (ko)	1998-06-01	수용성 약물에 대한 서방성 마이크로캡슐(Microcapsule)
KR0143767B1 (ko)	1998-07-15	소마토트로핀을 함유하는 지속성 조성물
KR100344330B1 (ko)	2002-11-30	지속성주사현탁제
Furr et al.	1984	Slow release formulation of ‘Zoladex’(ICI 118630) for the treatment of hormone responsive prostate and mammary tumours
Ogawa	1996	Monthly Microcapsule Depot Form of Leuprorelin: Animal Studies and Internal Structure of Microcapsules
Sanders et al.	1984	An injectable biodegradable controlled release delivery system for LHRH analogues